Traws Pharma Stock Discussion

$Traws Pharma (TRAW.US)$
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment
Expert Systems celebrates a milestone in the clinical development of tivoxavir marboxil, a potential one-time influenza treatment. Developed by Traws Pharma(NASDAQ: TRAW), tivoxavir showed positive topline Phase 1 safety and pharmacokinetic results, supporting its potential as a broad-spectrum flu treatment.
Expert Systems' AI-enabled drug discove...

$Traws Pharma (TRAW.US)$ Reuters· 1 min ago
Traws Pharma Inc - Preclinical Data Show Potent Inhibition of Drug-Resistant and Bird Flu Viruses

$Traws Pharma (TRAW.US)$
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Traws Pharma (NASDAQ: TRAW) announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza therapy, tivoxavir marboxil. The study demonstrated good overall tolerabilityand a pharmacokinetic profile supporting potential use as a one-time treatment for flu, including pandemic flu. Key findings include:
1. A single dose maintained ...

$Traws Pharma (TRAW.US)$
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
Phase 2a study expected to begin in H1 2025 in patients with COVID
Improving COVID care is an ongoing need, with approximately 50,000 US deaths in 2023
NEWTOWN, Pa., Sept. 30, 2024 (GLOB...

$Traws Pharma (TRAW.US)$ Reuters
1 min ago
Traws Pharma Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Traws Pharma Inc - Ratutrelvir Well-Tolerated, Achieved Consistent Plasma Levels Without Ritonavir

$Traws Pharma (TRAW.US)$ Low volume.. with high risk

$Traws Pharma (TRAW.US)$ Traws Pharma (Formerly Onconova) Granted European Patent EP4193988 For Solid Tumor Cancer Treatment Method

$Traws Pharma (TRAW.US)$ Traws Pharma Inc - Topline Phase 1 Data and Phase 2 Initiation Expected in H2 2024! So far has shown pre clinical activity against multiple Sars Cov 2 variants